Aduro Biotech, Inc. (NASDAQ:ADRO) VP Blaine Templeman sold 2,884 shares of the stock in a transaction on Monday, September 18th. The stock was sold at an average price of $11.20, for a total transaction of $32,300.80. Following the transaction, the vice president now directly owns 58,834 shares in the company, valued at $658,940.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Blaine Templeman also recently made the following trade(s):

  • On Wednesday, September 13th, Blaine Templeman sold 3,557 shares of Aduro Biotech stock. The stock was sold at an average price of $10.99, for a total transaction of $39,091.43.

Aduro Biotech, Inc. (NASDAQ ADRO) remained flat at $11.00 during trading on Wednesday. 236,393 shares of the stock were exchanged. The company’s market capitalization is $820.73 million. Aduro Biotech, Inc. has a 52 week low of $8.75 and a 52 week high of $15.52. The firm has a 50 day moving average of $11.50 and a 200-day moving average of $10.96.

Aduro Biotech (NASDAQ:ADRO) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.27) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.02). Aduro Biotech had a negative net margin of 609.58% and a negative return on equity of 43.92%. The business had revenue of $5.90 million for the quarter, compared to analysts’ expectations of $3.98 million. During the same period in the previous year, the company earned $0.03 EPS. Aduro Biotech’s revenue for the quarter was down 84.9% compared to the same quarter last year. On average, analysts predict that Aduro Biotech, Inc. will post ($1.37) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Insider Selling: Aduro Biotech, Inc. (ADRO) VP Sells 2,884 Shares of Stock” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/insider-selling-aduro-biotech-inc-adro-vp-sells-2884-shares-of-stock/1576548.html.

Several research analysts recently issued reports on ADRO shares. Zacks Investment Research raised shares of Aduro Biotech from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a research note on Tuesday, July 4th. Cowen and Company started coverage on shares of Aduro Biotech in a research note on Tuesday, July 18th. They set an “outperform” rating on the stock. BidaskClub raised shares of Aduro Biotech from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. HC Wainwright set a $18.00 target price on shares of Aduro Biotech and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Finally, Canaccord Genuity set a $30.00 target price on shares of Aduro Biotech and gave the stock a “buy” rating in a research note on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $19.00.

Several large investors have recently made changes to their positions in ADRO. Wellington Management Group LLP grew its stake in shares of Aduro Biotech by 9.1% during the 1st quarter. Wellington Management Group LLP now owns 9,448,529 shares of the biotechnology company’s stock valued at $101,571,000 after acquiring an additional 791,770 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Aduro Biotech by 283.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 372,348 shares of the biotechnology company’s stock valued at $4,244,000 after acquiring an additional 275,295 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Aduro Biotech by 330.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 236,721 shares of the biotechnology company’s stock valued at $2,545,000 after acquiring an additional 181,734 shares during the period. Renaissance Technologies LLC grew its stake in shares of Aduro Biotech by 762.1% during the 1st quarter. Renaissance Technologies LLC now owns 181,900 shares of the biotechnology company’s stock valued at $1,955,000 after acquiring an additional 160,800 shares during the period. Finally, Nexthera Capital LP bought a new position in shares of Aduro Biotech during the 2nd quarter valued at approximately $1,767,000. Institutional investors own 35.05% of the company’s stock.

About Aduro Biotech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.